A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

(2010) D Handolias et al.   BRITISH JOURNAL OF CANCER

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib

(2009) L. Jilaveanu et al.   CLINICAL CANCER RESEARCH

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E

(2009) Florian A. Karreth et al.   MOLECULAR CELL

“Tumor immunology meets oncology IV”, 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany

(2008) Juergen Bukur et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

(2008) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Major Response to Imatinib Mesylate in KIT-Mutated Melanoma

(2008) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells

(2008) E. Sala et al.   MOLECULAR CANCER RESEARCH

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

(2008) Jose Lutzky et al.   Pigment Cell & Melanoma Research

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improving Melanoma Classification by Integrating Genetic and Morphologic Features

(2008) Amaya Viros et al.   PLOS MEDICINE